PneumaCult™-ALI-S 培养基

无血清和无BPE，用于人小气道上皮细胞的气液界面培养

只有 %1 左

率先评论此产品

¥3,860.00

产品号 #（选择产品）

产品号 #05050_C

无血清和无BPE，用于人小气道上皮细胞的气液界面培养

产品优势

在PneumaCult™-ALI-S 中培养的人小气道上皮细胞（HSAEC）经历完全的粘膜纤毛分化，形成与体内小气道上皮高度相似的立方上皮结构。
PneumaCult™-ALI-S 不含血清和牛垂体提取物（BPE），能够最大程度地降低实验间差异。
PneumaCult™-ALI-S培养基和PneumaCult™-Ex Plus培养基构成一套
完整的优化体系，用于HSAEC 的扩增、维持及分化培养。

产品组分包括

PneumaCult™-ALI-S基础培养基，450 mL
PneumaCult™-ALI-S补充剂（10X）， 50 mL
PneumaCult™-ALI-S维持补充剂（100X）， 5 x 1mL

立即询价

总览

PneumaCult™-ALI-S培养基（产品号#05050）是一种无血清、无BPE的培养基，用于在人气液界面（ALI）培养人小气道上皮细胞。在PneumaCult™-ALI-S培养基中培养的小气道上皮细胞会发生广泛的黏液纤毛分化，形成一种立方上皮，展现出与人体小气道在体内相似的形态和功能特征。

PneumaCult™-ALI-S培养基与PneumaCult™-NGEx培养基（产品号#100-1505）共同组成一个完整的、无BPE的体外人小气道建模培养系统。该系统稳定且定义明确，是基础呼吸研究、毒理研究和药物开发的宝贵工具。

实验数据

PneumaCult™ Culture System Workflow for Small Airway Research

Figure 1. Overview of the PneumaCult™ Culture System for Small Airway Research

Expansion of human small airway epithelial cells (HSAEC) in submerged culture is performed with PneumaCult™-Ex Plus Medium. During the early Expansion Phase of the air-liquid interface (ALI) culture procedure, PneumaCult™-Ex Plus is applied to the apical and basal chambers. Upon reaching confluence, the culture is air-lifted by removing the culture medium from both chambers, and PneumaCult™-ALI-S is added to the basal chamber only. Differentiation into a mucociliary epithelium is obtained following 21+ days of incubation and can be maintained for more than one year.

Higher proliferation rate of HSAEC cultured in PneumaCult™-Ex Plus Medium compared with other.

Figure 2. HSAEC and HBEC Grow at a Higher Rate During Expansion When Cultured in PneumaCult™-Ex Plus Medium

Human small airway epithelial cells (HSAEC) and human bronchial epithelial cells (HBEC) cultured in PneumaCult™-Ex Plus Medium exhibited higher proliferation rate at every passage compared with cells cultured in Small Airway Epithelial Cell Growth Medium. Cryopreserved HSAEC were obtained commercially at passage 2 (P2) while HBEC were obtained at P1.

HSAEC cultured in PneumaCult™-ALI-S differentiate to form a thin, cuboidal epithelium representative of the small airway.

Figure 3. HSAEC Cultured at the ALI Using PneumaCult™-ALI-S Medium Differentiate to Form a Morphology Representative of the Small Airway Epithelium

Hematoxylin and eosin (H&E) staining of HSAEC and HBEC cultured in PneumaCult™-ALI-S or PneumaCult™-ALI Medium at P3, after 28 days. HSAEC differentiated at the ALI in PneumaCult™-ALI-S formed a thin, cuboidal epithelial layer representative of the in vivo small airway epithelium while HBEC differentiated in PneumaCult™-ALI formed a pseudostratified epithelium resembling the in vivo bronchial epithelium. The ALI cultures were fixed, paraffin-embedded, sectioned, and stained with H&E. All images were taken using a 40X objective. Insert membrane was 10 μm in thickness. Scale bar = 20 μm.

Small airway epithelium markers, SCGB1A1, SCGB3A2, were detected in HSAEC cultured in PneumaCult™-ALI-S Medium.

Figure 4. Small Airway Epithelium Markers Were Detected in HSAEC Cultured in PneumaCult™-ALI-S Medium

Confocal images of whole mount immunostained ALI cultures showing HSAEC and HBEC cultured in PneumaCult™-ALI-S or PneumaCult™-ALI Medium at P3, after 28 days. The ALI cultures were fixed and stained with antibodies for ciliated cells (AC-tubulin; green), club cells (SCGB1A1; magenta), and secretory protein (SCGB3A2; red). The nuclei were counterstained with DAPI (blue). Small airway epithelium markers, SCGB1A1 and SCGB3A2, were detected at higher levels in HSAEC cultured in PneumaCult™-ALI-S compared with HSAEC cultured in PneumaCult™-ALI and HBEC cultured in either PneumaCult™-ALI-S or PneumaCult™-ALI. All images were taken using a 63X objective.

Relative expression of SCGB1A1 and SCGB3A2 was higher in HSAEC cultured in PneumaCult™-ALI-S compared to PneumaCult™-ALI.

Figure 5. Relative Expression of Small Airway Epithelium Markers by qPCR Were Detected at Higher Levels in HSAEC Cultured in PneumaCult™-ALI-S Medium Compared with HSAEC Cultured in PneumaCult™-ALI

HSAEC and HBEC cultured in PneumaCult™-ALI-S or PneumaCult™-ALI Medium at P3. After 28-days of differentiation, the ALI cultures were analysed for small airway epithelium markers, SCGB1A1 and SCGB3A2. Gene of Interest expression was normalized to housekeeping gene, TBP, and expressed as relative quantity (RQ). Relative expression of SCGB1A1 and SCGB3A2 was higher in HSAEC cultured in PneumaCult™-ALI-S Medium compared with HSAEC cultured in PneumaCult™-ALI and HBEC cultured in either PneumaCult™-ALI-S or PneumaCult™-ALI. Relative expression of SCGB3A2 was not detectable in HBEC cultured in either PneumaCult™-ALI or PneumaCult™-ALI-S.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

PneumaCult™-ALI-S Medium

Catalog #

05050

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

PneumaCult™-ALI-S Medium

Catalog #

05050

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

PneumaCult™-ALI-S Medium

Catalog #

05050

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

PneumaCult™-ALI-S Medium

Catalog #

05050

Lot #

All

Language

English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

文献 (3)

Development of a miniaturized 96-Transwell air-liquid interface human small airway epithelial model. T. Bluhmki et al. Scientific reports 2020

Abstract

In order to overcome the challenges associated with a limited number of airway epithelial cells that can be obtained from clinical sampling and their restrained capacity to divide ex vivo,miniaturization of respiratory drug discovery assays is of pivotal importance. Thus,a 96-well microplate system was developed where primary human small airway epithelial (hSAE) cells were cultured at an air-liquid interface (ALI). After four weeks of ALI culture,a pseudostratified epithelium containing basal,club,goblet and ciliated cells was produced. The 96-well ALI cultures displayed a cellular composition,ciliary beating frequency,and intercellular tight junctions similar to 24-well conditions. A novel custom-made device for 96-parallelized transepithelial electric resistance (TEER) measurements,together with dextran permeability measurements,confirmed that the 96-well culture developed a tight barrier function during ALI differentiation. 96-well hSAE cultures were responsive to transforming growth factor $\beta$1 (TGF-$\beta$1) and tumor necrosis factor $\alpha$ (TNF-$\alpha$) in a concentration dependent manner. Thus,the miniaturized cellular model system enables the recapitulation of a physiologically responsive,differentiated small airway epithelium,and a robotic integration provides a medium throughput approach towards pharmaceutical drug discovery,for instance,in respect of fibrotic distal airway/lung diseases.

View publication

A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity Y. Li et al. eBioMedicine 2024 Nov

Abstract

Global dissemination of SARS-CoV-2 Omicron sublineages has provided a sufficient opportunity for natural selection,thus enabling beneficial mutations to emerge. Characterisation of these mutations uncovers the underlying machinery responsible for the fast transmission of Omicron variants and guides vaccine development for combating the COVID-19 pandemic. Through systematic bioinformatics analysis of 496,606 sequences of Omicron variants,we obtained 40 amino acid substitutions that occurred with high frequency in the S protein. Utilising pseudoviruses and a trans -complementation system of SARS-CoV-2,we identified the effect of high-frequency mutations on viral infectivity and elucidated the molecular mechanisms. Finally,we evaluated the impact of a key emerging mutation on the immune protection induced by the SARS-CoV-2 VLP mRNA vaccine in a murine model. We identified a proline-to-leucine substitution at the 1263rd residue of the Spike protein,and upon investigating the relative frequencies across multiple Omicron sublineages,we found a trend of increasing frequency for P1263L. The substitution significantly enhances the capacity for S-mediated viral entry and improves the immunogenicity of a virus-like particle mRNA vaccine. Mechanistic studies showed that this mutation is located in the FERM binding motif of the cytoplasmic tail and impairs the interaction between the S protein and the Ezrin/Radixin/Moesin proteins. Additionally,this mutation facilitates the incorporation of S proteins into SARS-CoV-2 virions. This study offers mechanistic insight into the constantly increasing transmissibility of SARS-CoV-2 Omicron variants and provides a meaningful optimisation strategy for vaccine development against SARS-CoV-2. This study was supported by grants from the National Key Research and Development Plan of China (2021YFC2302405,2022YFC2303200,2021YFC2300200 and 2022YFC2303400),the National Natural Science Foundation of China (32188101,32200772,82422049,82241082,32270182,82372254,82271872,82341046,32100755 and 82102389),Shenzhen Medical Research Fund (B2404002,A2303036),the Shenzhen Bay Laboratory Startup Fund (21330111),Shenzhen San-Ming Project for Prevention and Research on Vector-borne Diseases (SZSM202211023),Yunnan Provincial Science and Technology Project at Southwest United Graduate School (202302AO370010). The New Cornerstone Science Foundation through the New Cornerstone Investigator Program,and the Xplorer Prize from Tencent Foundation.

View publication

Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR Y. Huang et al. International Journal of Molecular Sciences 2025 May

Abstract

Cystic Fibrosis (CF) is a common genetic disease in the United States,resulting from mutations in the Cystic Fibrosis transmembrane conductance regulator (cftr) gene. CFTR modulators,particularly Elexacaftor/Tezacaftor/Ivacaftor (ETI),have significantly improved clinical outcomes for patients with CF. However,many CFTR mutations are not eligible for CFTR modulator therapy due to their rarity. In this study,we report that a patient carrying rare complex CFTR mutations,c.1680-877G>T and c.3067_3072delATAGTG,showed positive clinical outcomes after ETI treatment. We demonstrate that ETI was able to increase the expression of CFTR harboring c.3067_3072delATAGTG in a heterologous system. Importantly,patient-derived nasal epithelial cells in an air–liquid interface (ALI) culture showed improved CFTR function following ETI treatment. These findings supported the initiation of ETI with the patient. Retrospective studies have suggested that the patient has shown small but steady improvement over the past two years in several clinical metrics,including lung function,body mass index (BMI),and sweat chloride levels. Our studies suggest that ETI could be beneficial for patients carrying c.3067_3072delATAGTG.

View publication

View All Publications

更多信息
物种	人
配方	无血清

更多信息

物种

人

配方

无血清

PneumaCult™-ALI-S 培养基

产品号 #05050

产品号 #（选择产品）

产品号 #05050_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

PneumaCult™-ALI-S 培养基

产品号 #05050

产品号 #（选择产品）

产品号 #05050_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (21)

文献 (3)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台